Eli Lilly: $1 Trillion Pharma Giant? Fundamentals, Pipeline & Price Targets Explained

Eli Lilly (LLY): Is the $1,000 Stock Still a Buy — or a Breakdown Waiting to Happen?Forget Big Tech for a moment.There’s a pharmaceutical titan sprinting toward a potential $1 trillion valuation, reshaping healthcare — and possibly your portfolio.We’re talking about Eli Lilly (LLY).The stock surged above $1,000 per share, driven by blockbuster obesity and diabetes drugs, massive revenue beats, and a pipeline that could redefine modern medicine. But with the stock looking extremely expensive…Is LLY still a buy? Or does a major pullback make more sense?Let’s break it down.💊 Eli Lilly’s Explosive Growth: The Fundamentals🚀 Revenue Growth: +54% YoYQ3 revenue hit $17.6B, fueled by two mega-drugs:1️⃣ Mounjaro (Tirzepatide)* Type 2 diabetes treatment* $6.5B in Q3 sales (+100% YoY)* One of the fastest-growing drugs in pharma history2️⃣ Zepbound* Obesity / weight-loss drug* Approved for chronic weight management* Part of the fastest-expanding drug category in the worldThe obesity drug market could reach $80B by 2030 — and Lilly is dominating.EPS Blowout* Q3 EPS: $7.20* Analyst estimate: $5.89Lilly is printing money.Raised Guidance2025 revenue guidance: $63B–$63.5BManagement only guided one year out — but confidence is sky-high.🔬 The Real Long-Term Engine: The PipelineLLY is not a one-drug pony.Upcoming catalysts include:🟦 Orforglipron (Oral GLP-1)* Oral weight-loss pill* Eliminates injection barrier* Regulatory submissions planned for late 2025🧠 Donanemab (Alzheimer’s Treatment)* Full FDA approval* Huge unmet medical need* Prestige + long-term revenue potential* Adoption may be slow due to safety monitoring — but impact is enormousThis pipeline justifies Lilly’s premium valuation better than any other pharma giant.📉 The Bear Case: The Price Is… HighAt $1,000–$1,025, LLY is:* Overbought on the daily RSI (83+)* Approaching overbought on the weekly RSI (70)* Trading well above long-term moving averages* Roughly at intrinsic value based on some DCF modelsEven bulls admit:“LLY needs a pullback.”📈 Technical AnalysisTrend: Strongly bullishShort-term:* Pullback likely* Support near $900–$930* Ideal dip-buy zoneMedium-term:* Reasonable range: $1,000–$1,200Long-term:If pipeline delivers and Novo Nordisk doesn’t catch up:LLY could hit $1,500+.Analysts already project a high-end 12-month target of $1,500.Downside risk:If market corrects sharply →LLY could revisit $700s (unlikely without macro shock).🧠 Investor ConclusionEli Lilly is:✔ Fundamentally elite✔ Dominating the fastest-growing pharma segment✔ Backed by a pipeline that supports long-term growth✘ Very expensive in the short term✘ Technically overbought✘ Prime for a pullback before new highsShort-term: Expect volatility & potential pullbackLong-term: One of the strongest healthcare names on the planet This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit norbertbm.substack.com/subscribe